title: [Optimal way of administration of granulocyte colony stimulating factor in the treatment of urological cancer].
abstract: Granulocyte-Colony Stimulating Factor (G-CSF) was administered to patients with bladder cancer, ureteral cancer and testicular cancer following chemotherapy. Chemotherapy included 23 courses of M-VAC (Methotrexate, Vinblastine, Adriamycin, Cisplatin) therapy to patients with bladder cancer or ureteral cancer and 10 courses of EP (Etoposide, Cisplatin) therapy to patients with testicular cancer. During M-VAC chemotherapy, about a half of the patients experienced leukopenia below 3000/mm3 until the 11th day. Leukopenia failed to improve promptly when G-CSF was started after leukocytes decreased below 3000/mm3. On the other hand, 5-days of prophylactic administrations of G-CSF from the 9th day of M-VAC therapy were able to increase leukocytes promptly. In EP chemotherapy against testicular tumor, G-CSF was started on the 9th day and continued for 5 days. Leukocytes increased immediately and the average duration of leukopenia below 3000/mm3 was only 1.2 day. These results indicate that a short term of prophylactic administration of G-CSF following these chemotherapies is able to accelerate a recovery from leukopenia and decrease a risk of bacterial infection. G-CSF is proposed to be enrolled in the treatment of urological cancer for the improvement of safety and the outcome of therapy.
authors.affiliation: Department of Urology, Shinshu University School of Medicine.
authors.forename: T
authors.initials: T
authors.lastname: Okaneya
authors.forename: T
authors.initials: T
authors.lastname: Tsuruta
authors.forename: M
authors.initials: M
authors.lastname: Niwakawa
authors.forename: M
authors.initials: M
authors.lastname: Kawakami
authors.forename: S
authors.initials: S
authors.lastname: Kobayashi
authors.forename: A
authors.initials: A
authors.lastname: Ogawa
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced / Q000628:therapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D013736:Testicular Neoplasms / Q000097:blood / Q000628:therapy*; D014516:Ureteral Neoplasms / Q000097:blood / Q000628:therapy; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000628:therapy*; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D014747:Vinblastine; D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate